local_hospital

Rostock University Medical Center

Address
lock Available on a paid plan

Oncology and Hematologic Malignancies

At Rostock University Medical Center, a large share of trials focuses on cancer and blood cancers, including acute myeloid leukemia, lymphoma, multiple myeloma, prostate cancer, and colorectal cancer. These studies aim to improve treatment effectiveness, refine transplant-based care, and test newer combinations that may offer better disease control.

  • Acute leukemia and myelodysplastic syndromes evaluating improved treatment strategies before and after transplantation
  • Lymphomas and chronic lymphocytic leukemia: testing targeted and immune-based approaches to extend remission
  • Solid tumors such as prostate, breast, lung, and head and neck cancers: assessing new therapies and better disease monitoring

Many of these trials are designed to compare current standard care with newer options, with the goal of improving survival, reducing relapse, and supporting more personalized oncology treatment.

Neurology, Dementia, and Amyotrophic Lateral Sclerosis

The site also has strong activity in neurology and mental disorders, especially studies in Alzheimer’s disease, vascular dementia, multiple sclerosis, and amyotrophic lateral sclerosis. Research here is centered on finding better ways to slow disease progression, improve symptom control, and strengthen diagnostic accuracy.

  • Alzheimer’s disease and related dementias: evaluating treatments and imaging tools that may support earlier and more precise diagnosis
  • Amyotrophic lateral sclerosis: testing therapies intended to slow functional decline and improve safety
  • Relapsing multiple sclerosis: studying approaches that reduce new disease activity and support long-term control

Several trials focus on whether emerging therapies can better preserve quality of life and delay progression in these challenging neurological conditions.

Gastroenterology, Inflammatory Disease, and Dermatology

Another important research area at Rostock University Medical Center is gastroenterology and immune-mediated disease, alongside dermatology. Trials include Crohn’s disease, ulcerative colitis, atopic dermatitis, psoriasis, and hidradenitis suppurativa, with a focus on reducing inflammation and improving day-to-day symptoms.

  • Crohn’s disease and ulcerative colitis: testing new anti-inflammatory treatments for better disease control
  • Atopic dermatitis and plaque psoriasis: evaluating therapies that may reduce skin symptoms and improve comfort
  • Hidradenitis suppurativa: studying options for a difficult-to-treat chronic inflammatory skin condition

These studies aim to improve both symptom relief and long-term disease management for patients with chronic inflammatory disorders.

Cardiovascular, Respiratory, and Critical Care Research

The clinical trial portfolio also includes cardiovascular disease, respiratory disease, and critical care. Research topics range from atrial fibrillation and heart failure to asthma, severe lung infections, and care for critically ill patients. The overall aim is to improve prevention, safety, and treatment outcomes in high-risk settings.

  • Atrial fibrillation and stroke prevention: evaluating ways to reduce clot-related complications and bleeding risk
  • Asthma and severe respiratory illness: testing therapies that may improve breathing control and reduce exacerbations
  • Critical illness: studying supportive care strategies that may improve recovery in intensive care

This area reflects a strong interest in managing acute and chronic conditions where treatment decisions can have immediate impact on patient outcomes.

Urology, Imaging, and Procedural Care

Research in urology and diagnostic imaging is another visible theme, with studies in prostate cancer, bladder neoplasms, and related disease states. The site is also involved in trials evaluating imaging-based diagnosis and treatments that support procedures or urgent interventions.

  • Prostate cancer: assessing imaging tools and new treatment options for localized and metastatic disease
  • Urinary tract and bladder disorders: exploring better ways to identify and manage urologic disease
  • Urgent procedural care: testing approaches that help manage bleeding risk and treatment reversal when rapid intervention is needed

These trials combine practical clinical questions with efforts to improve precision in diagnosis and safety in treatment planning.

Pediatric Oncology and Rare Diseases

The site contributes to pediatric oncology and rare disease research, including acute lymphoblastic leukemia, lymphoblastic lymphoma, Ewing sarcoma, medulloblastoma, and other uncommon tumors. These studies focus on improving cure rates while limiting treatment burden for children and adolescents.

  • Childhood leukemia and lymphoma: testing optimized treatment strategies to improve survival and reduce relapse
  • Brain tumors and sarcomas: evaluating therapies intended to strengthen disease control in rare cancers
  • Genetic and high-risk pediatric cancers: studying more individualized approaches for difficult-to-treat disease

This research supports ongoing efforts to tailor care for younger patients with complex and often aggressive conditions.

Site Overview

assignment
145
connected trials
corporate_fare
85
sponsors
science
229
IMPs

Activity Indicator

Last 6 months

14
Trials started
-22% vs previous period.
18
Trials started 6–12 months ago
145
Total trials linked
Highly Active
trending_downDeclining-22%
3
1
3
4
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 18 therapeutic areas and 15 of 229 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 210 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
91
Sponsors (total)
85
Active sponsors
63

Sponsor Network

Top 63 by active trials.

lock +62 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +26 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
145
Outperforms 99% of sites
public
Therapeutic diversity
20areas
Outperforms 99% of sites
groups
Sponsor diversity
85sponsors
Outperforms 99% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Rostock University Medical Center

lock Showing 1 of 145 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) rolling over from the EASE SBS 2 or 3 trialsZealand Pharma A/SPhase IIINot RecruitingDec 2025

IMP list

lock Showing 1 of 229 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cytarabine13Unknown2017-07-122025-12-19

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.